Info@ThinkPinkRocks.org

Royal Philips (NYSE: PHG AEX: PHIA) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration to market its precision planning application for Transcatheter Aortic-Valve Implantation (TAVI) treatments.

Visit link:
Royal Philips receives 510(k) clearance from FDA for TAVI treatments

Scroll to Top